Search

Your search keyword '"Bessho, Kazuhiko"' showing total 298 results
Start Over Author "Bessho, Kazuhiko"
298 results on '"Bessho, Kazuhiko"'

19. Serum Amino Acid Profiling in Citrin-Deficient Children Exhibiting Normal Liver Function During the Apparently Healthy Period

Author

Miyazaki, Teruo, Nagasaka, Hironori, Komatsu, Haruki, Inui, Ayano, Morioka, Ichiro, Tsukahara, Hirokazu, Kaji, Shunsaku, Hirayama, Satoshi, Miida, Takashi, Kondou, Hiroki, Ihara, Kenji, Yagi, Mariko, Kizaki, Zenro, Bessho, Kazuhiko, Kodama, Takahiro, Iijima, Kazumoto, Yorifuji, Tohru, Matsuzaki, Yasushi, Honda, Akira, Baumgartner, Matthias, Series Editor, Patterson, Marc, Series Editor, Rahman, Shamima, Series Editor, Peters, Verena, Series Editor, Morava, Eva, Editor-in-Chief, and Zschocke, Johannes, Series Editor

Published
2019
Full Text
View/download PDF

27. Effect of food on the pharmacokinetics and therapeutic efficacy of 4-phenylbutyrate in progressive familial intrahepatic cholestasis

Author

Nakano, Satoshi, Osaka, Shuhei, Sabu, Yusuke, Minowa, Kei, Hirai, Saeko, Kondou, Hiroki, Kimura, Takeshi, Azuma, Yoshihiro, Watanabe, Satoshi, Inui, Ayano, Bessho, Kazuhiko, Nakamura, Hidefumi, Kusano, Hironori, Nakazawa, Atsuko, Tanikawa, Ken, Kage, Masayoshi, Shimizu, Toshiaki, Kusuhara, Hiroyuki, Zen, Yoh, Suzuki, Mitsuyoshi, and Hayashi, Hisamitsu

Published
2019
Full Text
View/download PDF

28. Serum Amino Acid Profiling in Citrin-Deficient Children Exhibiting Normal Liver Function During the Apparently Healthy Period

Author

Miyazaki, Teruo, primary, Nagasaka, Hironori, additional, Komatsu, Haruki, additional, Inui, Ayano, additional, Morioka, Ichiro, additional, Tsukahara, Hirokazu, additional, Kaji, Shunsaku, additional, Hirayama, Satoshi, additional, Miida, Takashi, additional, Kondou, Hiroki, additional, Ihara, Kenji, additional, Yagi, Mariko, additional, Kizaki, Zenro, additional, Bessho, Kazuhiko, additional, Kodama, Takahiro, additional, Iijima, Kazumoto, additional, Yorifuji, Tohru, additional, Matsuzaki, Yasushi, additional, and Honda, Akira, additional

Published
2018
Full Text
View/download PDF

30. Early detection of liver fibrosis with serum Mac-2 binding protein glycosylation-modified isomer (M2BPGi) during follow-up intestinal failure patients without intestinal failure–associated liver disease (IFALD)

Author

Ueno, Takehisa, primary, Takase, Koki, additional, Deguchi, Koichi, additional, Masahata, Kazunori, additional, Nomura, Motonari, additional, Watanabe, Miho, additional, Kamiyama, Masafumi, additional, Tazuke, Yuko, additional, Bessho, Kazuhiko, additional, and Okuyama, Hiroomi, additional

Published
2022
Full Text
View/download PDF

35. Clinical implications of serum autotoxin in regular follow up after pediatric living donor liver transplantation for biliary atresia

Author

1000010456957, Ueno, Takehisa, Takase, Koki, 1000010839369, Toyama, Chiyoshi, 1000000747082, Deguchi, Koichi, 1000040588381, Masahata, Kazunori, 1000040546909, Nomura, Motonari, 1000040791728, Watanabe, Miho, 1000020403074, Kamiyama, Masafumi, 1000010397698, Tazuke, Yuko, 1000080423169, Bessho, Kazuhiko, 1000030252670, Okuyama, Hiroomi, 1000010456957, Ueno, Takehisa, Takase, Koki, 1000010839369, Toyama, Chiyoshi, 1000000747082, Deguchi, Koichi, 1000040588381, Masahata, Kazunori, 1000040546909, Nomura, Motonari, 1000040791728, Watanabe, Miho, 1000020403074, Kamiyama, Masafumi, 1000010397698, Tazuke, Yuko, 1000080423169, Bessho, Kazuhiko, 1000030252670, and Okuyama, Hiroomi

Abstract

Background: : Pediatric patients sometimes develop graft fibrosis after living donor liver transplant (LDLT). Autotaxin is a recently developed serum marker for hepatic fibrosis. We studied the relationship between serum autotaxin levels and histological findings in patients after LDLT for biliary atresia (BA). Methods: Information on patients aged <19 years who received LDLT for BA and were followed for at least 1 year after LDLT was gathered. Autotaxin levels were compared with pathological fibrosis scores. Results: The study included 52 patients, of whom 4 patients had no fibrosis (F0), 36 patients had F1 fibrosis, and 12 patients had F2. The median serum autotaxin level was 0.89 mg/L. In patients with portal vein (PV) complications such as stenosis or thrombosis (n = 7), the mean autotoxin level was 1.25 mg/L compared with 0.95 mg/L in patients without PV complications (p = 0.004). Among patients without PV complications, the mean autotaxin level was 0.90, 0.88, and 1.18 mg/L in F0, F1, and F2 fibrosis, respectively. The mean autotaxin was higher in F2 fibrosis than in F0 or F1 fibrosis (p<0.05). Autotoxin had a high area under the curve (0.86) with the cut-off level of 0.897 mg/L. Conclusion: Serum autotaxin is a novel marker for liver fibrosis in patients after pediatric LDLT for BA. Type of study: : Study of Diagnostic Test. Level of evidence: : Level II.

Published
2022

36. Clinical practice guidelines for the management of children with mother‐to‐child transmitted hepatitis C virus infection

Author

Tajiri, Hitoshi, primary, Bessho, Kazuhiko, additional, Nakayama, Yoshiko, additional, Abukawa, Daiki, additional, Iitsuka, Yoshinori, additional, Ito, Yoshinori, additional, Inui, Ayano, additional, Etani, Yuri, additional, Suzuki, Mitsuyoshi, additional, Takano, Tomoko, additional, Tanaka, Atsushi, additional, Mizuochi, Tatsuki, additional, Miyoshi, Yoko, additional, and Murakami, Jun, additional

Published
2022
Full Text
View/download PDF

38. Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation

Author

Li, Jun, Razumilava, Nataliya, Gores, Gregory J., Walters, Stephanie, Mizuochi, Tatsuki, Mourya, Reena, Bessho, Kazuhiko, Wang, Yui-Hsi, Glaser, Shannon S., Shivakumar, Pranavkumar, and Bezerra, Jorge A.

Subjects
Physiological research, Immune response -- Research, Biliary atresia -- Physiological aspects, Interleukins -- Properties, Health care industry
Abstract

Injury to the biliary epithelium triggers inflammation and fibrosis, which can result in severe liver diseases and may progress to malignancy. Development of a type 1 immune response has been linked to biliary injury pathogenesis; however, a subset of patients with biliary atresia, the most common childhood cholangiopathy, exhibit increased levels of Th2-promoting cytokines. The relationship among different inflammatory drivers, epithelial repair, and carcinogenesis remains unclear. Here, we determined that the Th2-activating cytokine IL-33 is elevated in biliary atresia patient serum and in the livers and bile ducts of mice with experimental biliary atresia. Administration of IL-33 to WT mice markedly increased cholangiocyte proliferation and promoted sustained cell growth, resulting in dramatic and rapid enlargement of extrahepatic bile ducts. The IL-33-dependent proliferative response was mediated by an increase in the number of type 2 innate lymphoid cells (ILC2s), which released high levels of IL-13 that in turn promoted cholangiocyte hyperplasia. Induction of the IL-33/ILC2/IL-13 circuit in a murine biliary injury model promoted epithelial repair; however, induction of this circuit in mice with constitutive activation of AKT and YAP in bile ducts induced cholangiocarcinoma with liver metastases. These findings reveal that IL-33 mediates epithelial proliferation and suggest that activation of IL-33/ILC2/IL-13 may improve biliary repair and disruption of the circuit may block progression of carcinogenesis., Introduction Disruption of the epithelial lining of bile ducts triggers inflammation and fibrosis, which may manifest clinically as devastating inflammatory diseases in children (e.g., biliary atresia) and adults (e.g., sclerosing [...]

Published
2014
Full Text
View/download PDF

40. Reply

Author

Mourya, Reena, Bessho, Kazuhiko, Shivakumar, Pranavkumar, and Bezerra, Jorge A.

Published
2015
Full Text
View/download PDF

42. Th2 signals induce epithelial injury in mice and are compatible with the biliary atresia phenotype

Author

Li, Jun, Bessho, Kazuhiko, Shivakumar, Pranavkumar, Mourya, Reena, Mohanty, Sujit Kumar, Dos Santos, Jorge L., Miura, Irene K., Porta, Gilda, and Bezerra, Jorge A.

Subjects
Biliary atresia -- Diagnosis -- Care and treatment, Cellular signal transduction -- Research, Epithelial cells -- Genetic aspects, Phenotype -- Identification and classification, Health care industry
Abstract

Biliary atresia (BA) is a destructive cholangiopathy of childhood in which Th1 immunity has been mechanistically linked to the bile duct inflammation and obstruction that culminate in liver injury. Based [...]

Published
2011
Full Text
View/download PDF

48. Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents with Chronic HCV: Part 1 of the DORA Study

Author

Jonas, Maureen M, Squires, Robert H, Rhee, Susan M, Lin, Chih-Wei, Bessho, Kazuhiko, Feiterna-Sperling, Cornelia, Hierro, Loreto, Kelly, Deirdre, Ling, Simon C, Strokova, Tatiana, del Valle-Segarra, Antonio, Lovell, Sandra, Liu, Wei, Ng, Teresa I, Porcalla, Ariel, Gonzalez, Yuri Sanchez, Burroughs, Margaret, Sokal, Etienne, UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, and UCL - (SLuc) Service de gastro-entérologie et hépatologie pédiatrique

Subjects
Hepatology
Abstract

The pangenotypic regimen of glecaprevir and pibrentasvir (G/P) is approved to treat adults with chronic hepatitis C virus (HCV) infection, and has yielded high cure rates in adults in clinical trials. Approved treatment options for pediatrics may include ribavirin (RBV). A pangenotypic regimen for pediatric patients remains an unmet need. DORA is an ongoing phase 2/3, non-randomized, open-label study evaluating the pharmacokinetics (PK), safety, and efficacy of G/P in pediatric patients with chronic HCV. This analysis includes Part 1 of the study, conducted in adolescent patients 12-17 years old given the adult regimen of G/P (300 mg/120 mg) once-daily for 8-16 weeks according to the indication durations used in adults. Patients were either treatment-naïve or experienced with interferon (IFN)- based regimens. The primary PK endpoint was steady-state exposures for glecaprevir and pibrentasvir; the primary efficacy endpoint was sustained virologic response 12 weeks post-treatment (SVR12). The secondary efficacy endpoints were on-treatment virologic failure, relapse, and reinfection. Safety and tolerability were monitored. Part 1 enrolled 48 adolescent patients infected with genotypes 1, 2, 3, or 4; 47 of whom were administered G/P. All 47 patients (100%) achieved SVR12. No on-treatment virologic failures or relapses occurred. PK exposures of glecaprevir and pibrentasvir were comparable to exposures in adults. No AEs led to treatment discontinuation, and no serious AEs occurred. CONCLUSION: Adolescent patients with chronic HCV infection treated with G/P achieved a comparable exposure to adults, 100% SVR12 rate, and safety profile consistent with that in adults. This is the first pangenotypic regimen to demonstrate 100% efficacy within the adolescent population in as little as 8 weeks of treatment.

Published
2020

49. Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents with Chronic HCV: Part 1 of the DORA Study

Author

UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service de gastro-entérologie et hépatologie pédiatrique, Jonas, Maureen M, Squires, Robert H, Rhee, Susan M, Lin, Chih-Wei, Bessho, Kazuhiko, Feiterna-Sperling, Cornelia, Hierro, Loreto, Kelly, Deirdre, Ling, Simon C, Strokova, Tatiana, del Valle-Segarra, Antonio, Lovell, Sandra, Liu, Wei, Ng, Teresa I, Porcalla, Ariel, Gonzalez, Yuri Sanchez, Burroughs, Margaret, Sokal, Etienne, UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service de gastro-entérologie et hépatologie pédiatrique, Jonas, Maureen M, Squires, Robert H, Rhee, Susan M, Lin, Chih-Wei, Bessho, Kazuhiko, Feiterna-Sperling, Cornelia, Hierro, Loreto, Kelly, Deirdre, Ling, Simon C, Strokova, Tatiana, del Valle-Segarra, Antonio, Lovell, Sandra, Liu, Wei, Ng, Teresa I, Porcalla, Ariel, Gonzalez, Yuri Sanchez, Burroughs, Margaret, and Sokal, Etienne

Abstract

The pangenotypic regimen of glecaprevir and pibrentasvir (G/P) is approved to treat adults with chronic hepatitis C virus (HCV) infection, and has yielded high cure rates in adults in clinical trials. Approved treatment options for pediatrics may include ribavirin (RBV). A pangenotypic regimen for pediatric patients remains an unmet need. DORA is an ongoing phase 2/3, non-randomized, open-label study evaluating the pharmacokinetics (PK), safety, and efficacy of G/P in pediatric patients with chronic HCV. This analysis includes Part 1 of the study, conducted in adolescent patients 12-17 years old given the adult regimen of G/P (300 mg/120 mg) once-daily for 8-16 weeks according to the indication durations used in adults. Patients were either treatment-naïve or experienced with interferon (IFN)- based regimens. The primary PK endpoint was steady-state exposures for glecaprevir and pibrentasvir; the primary efficacy endpoint was sustained virologic response 12 weeks post-treatment (SVR12). The secondary efficacy endpoints were on-treatment virologic failure, relapse, and reinfection. Safety and tolerability were monitored. Part 1 enrolled 48 adolescent patients infected with genotypes 1, 2, 3, or 4; 47 of whom were administered G/P. All 47 patients (100%) achieved SVR12. No on-treatment virologic failures or relapses occurred. PK exposures of glecaprevir and pibrentasvir were comparable to exposures in adults. No AEs led to treatment discontinuation, and no serious AEs occurred. CONCLUSION: Adolescent patients with chronic HCV infection treated with G/P achieved a comparable exposure to adults, 100% SVR12 rate, and safety profile consistent with that in adults. This is the first pangenotypic regimen to demonstrate 100% efficacy within the adolescent population in as little as 8 weeks of treatment.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results